Last reviewed · How we verify

Oupushifang Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Oupushifang Pharmaceutical Technology Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Atropine sulfate eye drops 0.01% Atropine sulfate eye drops 0.01% phase 3 Muscarinic receptor antagonist Muscarinic acetylcholine receptors (M1, M3) Ophthalmology
Atropine sulfate eye drops 0.02% Atropine sulfate eye drops 0.02% phase 3 Anticholinergic agent / Muscarinic receptor antagonist Muscarinic acetylcholine receptors (M1-M5, primarily M1 and M3) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. KYU-SUNG LEE · 1 shared drug class
  2. LitePharmTech Co., Ltd. · 1 shared drug class
  3. Massachusetts Eye and Ear Infirmary · 1 shared drug class
  4. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class
  5. R-Pharm · 1 shared drug class
  6. Shanghai Eye Disease Prevention and Treatment Center · 1 shared drug class
  7. University of California, San Francisco · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Oupushifang Pharmaceutical Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Oupushifang Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oupushifang-pharmaceutical-technology-co-ltd. Accessed 2026-05-16.

Related